Good morning to all,

Pr. Mark FEBBRAIO, from the Monash Institute of Pharmaceutical Sciences (Australia) will present his work.

Novel insights into the detection and treatment of non-alcoholic steatohepatitis (NASH)

Come and join us!


Professor Mark Febbraio is a Senior Principal Research Fellow and Investigator of the NHMRC, Australia and the Head of the Cellular and Molecular Metabolism Laboratory within the Drug Discovery Program at Monash Institute of Pharmaceutical Sciences, Monash University Australia. He is also the Founder and CSO of the recently incorporated company Celesta Therapeutics. His research is focussed on understanding mechanisms associated with exercise, obesity, type 2 diabetes and cancer and his aim is to develop novel drugs to treat lifestyle related diseases. He has authored over 280 peer reviewed papers in leading journals and has over 40,000 career citations. Throughout his career, he has many prestigious awards including the A K McIntyre Prize for significant contributions to Australian Physiological Science (1999), the Kellion Award for the Australian Diabetes Society (2017), The Eureka Scientific Prize (2020), The GSK Award for Research Excellence (2020) and The Endocrinology Society UK International Medallist (2021).